Trial · NCT07282210
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hb response rate | 24 Weeks | Proportion of participants achieving an increase in Hb of \> 1 g/dL from baseline |
| Secondary | Change from baseline in Hb (g/dL) | 24 Weeks | |
| Secondary | Change from baseline in lactate dehydrogenase (LDH) (u/L) | 24 Weeks | |
| Secondary | Change from baseline in indirect bilirubin (µmol/L) | 24 Weeks | |
| Secondary | Change from baseline in reticulocyte count (%) | 24 Weeks | |
| Secondary | Proportion of participants with a Hb increase of > 2g/dL from baseline | 24 Weeks | |
| Secondary | Percent change from baseline in urine albumin-creatinine ratio (uACR) | 24 Weeks | |
| Secondary | Change from baseline in overall score and subscale domain scores of the Participant-Reported Outcomes Measurement Information System (PROMIS) | 24 Weeks | The PROMIS-29 assessment for adult participants assesses depressive symptoms, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities. The PROMIS Pediatric-25 assessment for participants \<18 years of age assesses depressive symptoms, anxiety, physical function and mobility, pain interference, fatigue, and peer relationships. For both PROMIS assessments, a higher score indicates worse symptoms except for higher physical function values which indicate better physical function. |
| Secondary | Sickle cell disease complication rate | 24 Weeks | Proportion of participants experiencing at least one new or worsening hemolytic complication at any time during the study |
| Secondary | Proportion of participants with at least one category of improvement from baseline in Clinician and Patient Global Impression of Change | 24 Weeks | |
| Secondary | Frequency of acute sickle cell-related painful crises | 28 Weeks | |
| Secondary | Incidence of AEs, SAEs, and sickle cell disease related AEs | 28 Weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07282210/registered